Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

  • Sort by:
  • Browse by:
<< first | < prev page: of 12 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 9 10 11 12 presentations: 1 to 50 of 572
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
DRUG-DRUG INTERACTIONS IN HIV-ASSOCIATED TB: BALANCING EVIDENCE, RISK, AND PRAGMATISM   (ABSTRACT 1159)
Gary Maartens
University of Cape Town, Cape Town , South Africa
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
EFAVIRENZ PHARMACOKINETICS IN HIV/TB COINFECTED PERSONS RECEIVING RIFAPENTINE   (ABSTRACT 455)
Anthony Podany
University of Nebraska, Omaha, NE, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
EFAVIRENZ PHARMACOKINETICS WITH RIFAMPIN DOUBLE DOSE IN TB-HIV INFECTED PATIENTS   (ABSTRACT 456)
Daniel Warren Atwine
MSF-Epicentre, Mbarara, Uganda
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
PHARMACOKINETICS OF EFAVIRENZ 400MG WITH ISONIAZID/RIFAMPICIN IN PEOPLE WITH HIV   (ABSTRACT 457)
Maddalena Cerrone
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, UK, LONDON, United Kingdom
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
IN SILICO DRUG INTERACTION OF LONG-ACTING RILPIVIRINE AND CABOTEGRAVIR WITH RIFAMPIN   (ABSTRACT 458)
Rajith Kumar Reddy Rajoli
University of Liverpool, Liverpool, Merseyside, United Kingdom
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
THEMED DISCUSSION MODERATOR
Viviana A. Simon
Icahn School of Medicine at Mt Sinai, New York, NY, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
NEF UPREGULATES FASL EARLY WHILE MHCS ARE DOWNREGULATED LATE IN HIV-INFECTED CELLS   (ABSTRACT 186)
Rodrigo Matus-Nicodemos
Vaccine Research Center, NIAID, NIH, Bethesda, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
HIV-1 CORE MORPHOLOGY ASSESSMENT USING SINGLE VIRION IMAGING BASED ON FRET   (ABSTRACT 185)
Anamaria Daniela Sarca
Kyoto University, Kyoto, Kyoto, Japan
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
VISUALISATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 CDNA BY CLICK CHEMISTRY   (ABSTRACT 187)
Frauke Christ
Katholieke University Leuven, Leuven, Belgium
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
UBP43 (USP18) ABROGATES INTERFERON AND SAMHD1-MEDIATED RESTRICTION OF HIV-1   (ABSTRACT 189)
Edmund Osei-Kuffour
Heinrich-Heine-University Hospital, Düsseldorf, Germany
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
VPR ENHANCES VIRAL GENE EXPRESSION FROM UNINTEGRATED DNA IN A DCAF1-DEPENDENT MANNER   (ABSTRACT 190)
Sarah B Nodder
Boston University, Boston, MA, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: EARLY EVENTS: METHODS AND MECHANISMS
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
THEMED DISCUSSION MODERATOR
Adeeba Kamarulzaman
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
HIV DIAGNOSES AMONG PEOPLE WHO INJECT DRUGS - UNITED STATES, 2010–2016   (ABSTRACT 970)
Sheryl Lyss
Centers for Disease Control and Prevention, Atlanta, GA, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
CHARACTERISTICS OF HIV INCIDENT INFECTIONS AMONG PERSONS WHO INJECT DRUGS IN THE US   (ABSTRACT 971)
Christine Agnew-Brune
CDC, Atlanta, GA, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
NEW DIAGNOSES OF HIV AMONG INJECTING DRUG USERS, NEW YORK CITY 2006-2016   (ABSTRACT 973)
Lucia VanOgle Torian
NYC Department of Health and Mental Hygiene, New York, NY, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
DRUG OVERDOSE DEATHS AMONG PERSONS WITH HIV IN NEW YORK CITY, 2007-2015   (ABSTRACT 974)
Sarah Lomax Braunstein
New York City Department of Health and Mental Hygiene, Long island city, NY, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
3-YEAR OUTCOMES OF PATIENT NAVIGATION+FINANCIAL INCENTIVES FOR HIV+ SUBSTANCE USERS   (ABSTRACT 975)
Daniel Feaster
University of Miami, Miami, FL, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV IN PEOPLE WHO INJECT DRUGS: AN EVOLVING AND PERSISTENT CHALLENGE
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
THEMED DISCUSSION MODERATOR
Jennifer Jao
Icahn School of Medicine at Mt Sinai, New York, NY, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
LOPINAVIR/RITONAVIR INDUCES MITOCHONDRIAL TOXICITY IN HIV-EXPOSED UNINFECTED CHILDREN   (ABSTRACT 878)
Audrey Monnin
INSERM, Montpellier, France
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
HEU BLOOD MTDNA CONTENT REMAINS ELEVATED FROM BIRTH INTO EARLY LIFE (0-3 YEARS)   (ABSTRACT 879)
Abhinav Ajaykumar
University of British Columbia, Vancouver, BC, Canada
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
INCREASED INFLAMMATION AND MONOCYTE ACTIVATION IN HIV-EXPOSED UNINFECTED INFANTS   (ABSTRACT 880)
Grace A. McComsey
University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
INNATE IMMUNE ACTIVATION AMONG HIV-1 EXPOSED UNINFECTED INFANTS FROM BOTSWANA   (ABSTRACT 881)
Pilar Garcia Broncano
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
MICROBIAL TRANSLOCATION, IMMUNE ACTIVATION, AND GUT DYSBIOSIS IN HIV-EXPOSED INFANTS   (ABSTRACT 882)
Charles DeBeaux Mitchell
University of Miami, Miami, FL, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: HIV-EXPOSED INFANTS: ARE THEY DIFFERENT AND WHY?
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
THEMED DISCUSSION MODERATOR
Satish Gopal
University of North Carolina Project–Malawi, Lilongwe, Malawi
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
HIV AND CANCER RISK IN CONTEXT OF HIGH ART COVERAGE IN BOTSWANA   (ABSTRACT 649)
Scott Dryden-Peterson
Brigham and Women's Hospital, Boston, MA, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
SOUTH AFRICAN HIV CANCER MATCH STUDY: A PILOT STUDY TOWARDS PRECISION PUBLIC HEALTH   (ABSTRACT 650)
Mazvita Sengayi
National Health Laboratory Services, Johannesburg, South Africa
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
LEEP TREATMENT OF EXTENSIVE CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV-INFECTED WOMEN   (ABSTRACT 658)
Michael H. Chung
University of Washington, Seattle, WA, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
GENE PROFILE INFORMS HPV GRADE BUT NOT RELAPSE AFTER LEEP IN ART-SUPPRESSED HIV+HPV+   (ABSTRACT 659)
Emmanouil Papasavvas
The Wistar Institute, Philadelphia, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
KNOWLEDGE OF KAPOSI SARCOMA (KS) AND HIV AMONG TRADITIONAL HEALERS IN ZIMBABWE   (ABSTRACT 655)
Suzanne Pressler Fiorillo
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: THE EVOLVING EPIDEMIOLOGY AND PATHOGENESIS OF HIV-ASSOCIATED MALIGNANCIES IN SUB-SAHARAN AFRICA
QUESTIONS AND ANSWERS
from CROI 2018 on March 5, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
THEMED DISCUSSION MODERATOR
Linda Chang
University of Maryland, Baltimore, MD, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
CEREBRAL GLUTATHIONE METABOLISM IN ACUTE HIV INFECTION AND RESPONSE TO ART   (ABSTRACT 437)
Napapon Sailasuta
University of Hawaii, Honolulu, HI, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
AMYLOID UPTAKE BY PET IMAGING SUGGEST PREMATURE AGING IN OLDER HIV+ INDIVIDUALS   (ABSTRACT 438)
Ned W Sacktor
Johns Hopkins University, Baltimore, CA, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
NEUROIMAGING CORRELATES OF FRAILTY, COGNITION, AND HIV   (ABSTRACT 439)
Jeremy Strain
Washington University School of Medicine, St. Louis, MO, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
SUBCLINICAL GLOBAL AND THALAMIC HYPOMETABOLISM ON FDG-PET IN TREATED HIV+ SUBJECTS   (ABSTRACT 440)
Dima A. Hammoud
National Institutes of Health, Bethesda, MD, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
BRAIN VOLUMES CHANGES AFTER ABC/3TC + EFV OR TDF/FTC + ATV/R AS FIRST-LINE ART   (ABSTRACT 425)
Ignacio Pérez-Valero
Hospital La Paz, Madrid, Spain
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: AGING BRAIN AND HIV: BEFORE AND AFTER
QUESTIONS AND ANSWERS
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
THEMED DISCUSSION MODERATOR
Gerardo Garcia-Lerma
Centers for Disease Control and Prevention, Atlanta , GA, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
LOW PREVALENCE OF INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE ACROSS BOTSWANA   (ABSTRACT 542)
Simani Gaseitsiwe
Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
HIGH LEVEL RESISTANCE TO DOLUTEGRAVIR (DTG) AFTER EMERGENCE OF T97A MUTATION   (ABSTRACT 543)
Safia S Kuriakose
Leidos Biomedical Research, Inc, Bethesda, MD, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
UNINTEGRATED VIRAL DNA INVOLVED IN DOLUTEGRAVIR RESISTANCE   (ABSTRACT 544)
Olivier Delelis
École Normale Supérieure de Cachan, Cachan, France
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
PREVALENCE AND CLINICAL IMPACT OF MINORITY RESISTANT VARIANTS TO INTEGRASE INHIBITORS   (ABSTRACT 545)
Thuy Thi Thu Nguyen
Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, PARIS, France
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
INTEGRASE INHIBITOR RESISTANCE SELECTIONS INITIATED WITH DRUG RESISTANT HIV-1   (ABSTRACT 546)
Kristen Andreatta
Gilead Sciences, Foster City, CA, USA
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: ARE INTEGRASE STRAND TRANSFER INHIBITORS RESISTANCE PROOF?
QUESTIONS AND ANSWERS
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: BONES OF CONTENTION
THEMED DISCUSSION MODERATOR
Eugènia Negredo
Fundació Lluita Contra la Sida, Badalona, Spain
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
THEMED DISCUSSION: BONES OF CONTENTION
TDF PROPHYLAXIS FOR PMTCT OF HBV: EFFECT ON MATERNAL AND INFANT BONE MINERAL DENSITY   (ABSTRACT 720)
Gonzague Jourdain
Institut de recherche pour le développement, Chiang Mai, Chiang Mai, Thailand
from CROI 2018 on March 6, 2018 1:30 PM-2:30 PM
<< first | < prev page: of 12 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 9 10 11 12 presentations: 1 to 50 of 572